Allogene Therapeutics's market cap is currently ―. The company's EPS TTM is $-2.089; its P/E ratio is -1.61; Allogene Therapeutics is scheduled to report earnings on May 1, 2024, and the estimated EPS forecast is $-0.41. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ -44.00K	$ 43.00K	$ 44.00K	$ 52.00K	$ 47.00K
Gross Profit	$ -44.00K	$ 43.00K	$ 44.00K	$ 52.00K	$ 47.00K
EBIT	$ -89.21M	$ -61.31M	$ -77.99M	$ -98.70M	$ -98.10M
EBITDA	$ -85.73M	$ -57.74M	$ -74.35M	$ -95.20M	$ -95.03M
Net Income Common Stockholders	$ -89.26M	$ -61.31M	$ -77.99M	$ -98.70M	$ -94.85M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 448.70M	$ 465.50M	$ 491.96M	$ 471.22M	$ 517.32M
Total Assets	$ 642.84M	$ 712.33M	$ 770.97M	$ 746.87M	$ 817.06M
Total Debt	$ 88.35M	$ 90.10M	$ 91.82M	$ 93.51M	$ 95.12M
Net Debt	$ -360.35M	$ -375.40M	$ -400.14M	$ -377.71M	$ -422.20M
Total Liabilities	$ 130.60M	$ 129.22M	$ 148.06M	$ 154.61M	$ 1.22B
Stockholders Equity	$ 512.23M	$ 583.10M	$ 622.91M	$ 592.26M	$ 1.07B
Cash Flow	-
Free Cash Flow	$ -53.89M	$ -55.54M	$ -62.15M	$ -67.67M	$ -63.79M
Operating Cash Flow	$ -53.71M	$ -55.53M	$ -61.86M	$ -66.64M	$ -62.10M
Investing Cash Flow	$ 67.46M	$ -34.27M	$ 17.16M	$ 112.94M	$ 49.60M
Financing Cash Flow	$ 155.00K	$ 4.29M	$ 89.52M	$ 1.73M	$ 46.00K

Currency in USD

Allogene Therapeutics Earnings and Revenue History

Income Statement >

Allogene Therapeutics Debt to Assets

Balance Sheet >

Allogene Therapeutics Cash Flow

Cash Flow >

Allogene Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing